Pedro Pinto

Pedro Pinto

Auto-generated profile, based on publicly available information

Pedro Pinto

Department of Genetics, Portuguese Oncology Institute, Porto, Portugal

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2017 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JLJulie Lecarpentier
Julie Lecarpentier
VSValentina Silvestri
Valentina Silvestri
KKKaroline B. Kuchenbaecker
Karoline B. Kuchenbaecker
DBDaniel Barrowdale
Daniel Barrowdale
JDJoe Dennis
Joe Dennis
LOLaura Ottini
Laura Ottini
Purpose: BRCA1/2 mutations increase the risk of breast and prostate cancer in men. Common genetic variants modify cancer risks for female carriers of BRCA1/2 mutations. We investigated—for the first time to our knowledge—associations of common genetic variants with breast and prostate cancer risks for male carriers of BRCA1/ 2 mutations and implications for cancer risk prediction. Materials and Methods: We genotyped 1,802 male carriers of BRCA1/2 mutations from the Consortium of Investigators of Modifiers of BRCA1/2 by using the custom Illumina OncoArray. We investigated the combined effects of established breast and prostate cancer susceptibility variants on cancer risks for male carriers of BRCA1/2 mutations by constructing weighted polygenic risk scores (PRSs) using published effect estimates as weights. Results: In male carriers of BRCA1/2 mutations, PRS that was based on 88 female breast cancer susceptibility variants was associated with breast cancer risk (odds ratio per standard deviation of PRS, 1.36; 95% CI, 1.19 to 1.56; P = 8.6 × 10−6). Similarly, PRS that was based on 103 prostate cancer susceptibility variants was associated with prostate cancer risk (odds ratio per SD of PRS, 1.56; 95% CI, 1.35 to 1.81; P = 3.2 × 10−9). Large differences in absolute cancer risks were observed at the extremes of the PRS distribution. For example, prostate cancer risk by age 80 years at the 5th and 95th percentiles of the PRS varies from 7% to 26% for carriers of BRCA1 mutations and from 19% to 61% for carriers of BRCA2 mutations, respectively. Conclusion: PRSs may provide informative cancer risk stratification for male carriers of BRCA1/2 mutations that might enable these men and their physicians to make informed decisions on the type and timing of breast and prostate cancer risk management.

12 October 2012 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
AOAli Amin Al Olama
Ali Amin Al Olama
ZKZsofia Kote-Jarai
Zsofia Kote-Jarai
FSFredrick Schumacher
Fredrick Schumacher
FWFredrik Wiklund
Fredrik Wiklund
SBSonja I. Berndt
Sonja I. Berndt
RERosalind Eeles
Rosalind Eeles
Genome-wide association studies (GWAS) have identified multiple common genetic variants associated with an increased risk of prostate cancer (PrCa), but these explain less than one-third of the heritability. To identify further susceptibility alleles, we conducted a meta-analysis of four GWAS including 5953 cases of aggressive PrCa and 11 463 controls (men without PrCa). We computed association tests for approximately 2.6 million SNPs and followed up the most significant SNPs by genotyping 49 121 samples in 29 studies through the international PRACTICAL and BPC3 consortia. We not only confirmed the association of a PrCa susceptibility locus, rs11672691 on chromosome 19, but also showed an association with aggressive PrCa [odds ratio = 1.12 (95% confidence interval 1.03–1.21), P = 1.4 × 10−8]. This report describes a genetic variant which is associated with aggressive PrCa, which is a type of PrCa associated with a poorer prognosis.

16 April 2018 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
PPPaula Paulo
Paula Paulo
SMSofia Maia
Sofia Maia
CPCarla Pinto
Carla Pinto
PPPedro Pinto
Pedro Pinto
AMAugusta Monteiro
Augusta Monteiro
MTManuel R. Teixeira
Manuel R. Teixeira
Considering that mutations in known prostate cancer (PrCa) predisposition genes, including those responsible for hereditary breast/ovarian cancer and Lynch syndromes, explain less than 5% of early-onset/familial PrCa, we have sequenced 94 genes associated with cancer predisposition using next generation sequencing (NGS) in a series of 121 PrCa patients. We found monoallelic truncating/functionally deleterious mutations in seven genes, including ATM and CHEK2, which have previously been associated with PrCa predisposition, and five new candidate PrCa associated genes involved in cancer predisposing recessive disorders, namely RAD51C, FANCD2, FANCI, CEP57 and RECQL4. Furthermore, using in silico pathogenicity prediction of missense variants among 18 genes associated with breast/ovarian cancer and/or Lynch syndrome, followed by KASP genotyping in 710 healthy controls, we identified “likely pathogenic” missense variants in ATM, BRIP1, CHEK2 and TP53. In conclusion, this study has identified putative PrCa predisposing germline mutations in 14.9% of early-onset/familial PrCa patients. Further data will be necessary to confirm the genetic heterogeneity of inherited PrCa predisposition hinted in this study. Prostate cancer (PrCa) is the most frequent cancer diagnosed in men worldwide, estimated to be responsible for the death of 27,540 men in the United States in 2015. Contrarily to other cancer types, the genetic contribution to the 10–20% of PrCa cases occurring in families with aggregation of the disease is largely unknown. Germline mutations in the BRCA2 and the MSH2 breast and colon cancer predisposing genes, respectively, explain only about 1.5% of our early-onset/familial PrCa cases. Taking advantage of recent deep sequencing technologies and an analysis pipeline established in our group, we have screened 121 PrCa patients with strong evidence of an hereditary component for mutations in 94 genes involved in several cancer predisposing syndromes. We found truncating/functionally deleterious mutations in seven genes and “likely pathogenic” missense variants in four genes, of which five and one, respectively, have not been previously associated with PrCa predisposition. We believe this study significantly contributes to the understanding of the genetic heterogeneity behind early-onset/familial PrCa.

1 August 2020 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
VSValentina Silvestri
Valentina Silvestri
GLGoska Leslie
Goska Leslie
DBDaniel R. Barnes
Daniel R. Barnes
TGthe CIMBA Group
the CIMBA Group
BABjarni A. Agnarsson
Bjarni A. Agnarsson
LOLaura Ottini
Laura Ottini
While there are a substantial number of studies on cancer risks and the cancer spectrum in female carriers of germline pathogenic variants (PVs) in BRCA1 (OMIM 113705) and BRCA2 (OMIM 600185),1-4 data on male BRCA1/2 PV carriers are limited and have primarily focused on breast and/or prostate cancers. Population-based studies have shown that BRCA1 and BRCA2 PVs account for up to 2% and 13% of male breast cancer cases, respectively.5 The lifetime risk of male breast cancer has been estimated at 1% to 5% for BRCA1 and 5% to 10% for BRCA2 PV carriers, vs 0.1% in the general male population.2,3,6-8 Quiz Ref ID Additionally, BRCA1 and BRCA2 PVs have been estimated to account for less than 1% and approximately 2% of incident prostate cancer diagnoses, respectively.9,10 Estimates of lifetime prostate cancer risk associated with BRCA1 and BRCA2 PVs vary, with some studies reporting higher risk for male BRCA2 PV carriers,10-15 while other studies did not find any increased risk.16-18 Pathogenic variants in BRCA1 and, more frequently, in BRCA2 have been reported in male patients diagnosed with other cancer types.13,14,19-24 However, current risk estimates for cancers other than breast and prostate are based on handfuls of cases in a limited number of families.

15 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SMSofia Maia
Sofia Maia
MCMarta Cardoso
Marta Cardoso
PPPedro Pinto
Pedro Pinto
MPManuela Pinheiro
Manuela Pinheiro
CSCatarina Gomes Rodrigues Santos
Catarina Gomes Rodrigues Santos
MTManuel R. Teixeira
Manuel R. Teixeira
The HOXB13 germline variant G84E (rs138213197) was recently described in men of European descent, with the highest prevalence in Northern Europe. The G84E mutation has not been found in patients of African or Asian ancestry, which may carry other HOXB13 variants, indicating allelic heterogeneity depending on the population. In order to gain insight into the full scope of coding HOXB13 mutations in Portuguese prostate cancer patients, we decided to sequence the entire coding region of the HOXB13 gene in 462 early-onset or familial/hereditary cases. Additionally, we searched for somatic HOXB13 mutations in 178 prostate carcinomas to evaluate their prevalence in prostate carcinogenesis. Three different patients were found to carry in their germline DNA two novel missense variants, which were not identified in 132 control subjects. Both variants are predicted to be deleterious by different in silico tools. No somatic mutations were found. These findings further support the hypothesis that different rare HOXB13 mutations may be found in different ethnic groups. Detection of mutations predisposing to prostate cancer may require re-sequencing rather than genotyping, as appropriate to the population under investigation.

28 July 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
DBDaniel Barnes
Daniel Barnes
VSValentina Silvestri
Valentina Silvestri
GLGoska Leslie
Goska Leslie
LMLesley McGuffog
Lesley McGuffog
JDJoe Dennis
Joe Dennis
ECEmbrace Collaborators
Embrace Collaborators
Recent population-based female breast cancer and prostate cancer polygenic risk scores (PRS) have been developed. We assessed the associations of these PRS with breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers. 483 BRCA1 and 1318 BRCA2 European ancestry male carriers were available from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). A 147-single nucleotide polymorphism (SNP) prostate cancer PRS (PRSPC) and a 313-SNP breast cancer PRS were evaluated. There were 3 versions of the breast cancer PRS, optimized to predict overall (PRSBC), estrogen receptor (ER)–negative (PRSER-), or ER-positive (PRSER+) breast cancer risk. PRSER+ yielded the strongest association with breast cancer risk. The odds ratios (ORs) per PRSER+ standard deviation estimates were 1.40 (95% confidence interval [CI] =1.07 to 1.83) for BRCA1 and 1.33 (95% CI = 1.16 to 1.52) for BRCA2 carriers. PRSPC was associated with prostate cancer risk for BRCA1 (OR = 1.73, 95% CI = 1.28 to 2.33) and BRCA2 (OR = 1.60, 95% CI = 1.34 to 1.91) carriers. The estimated breast cancer odds ratios were larger after adjusting for female relative breast cancer family history. By age 85 years, for BRCA2 carriers, the breast cancer risk varied from 7.7% to 18.4% and prostate cancer risk from 34.1% to 87.6% between the 5th and 95th percentiles of the PRS distributions. Population-based prostate and female breast cancer PRS are associated with a wide range of absolute breast and prostate cancer risks for male BRCA1 and BRCA2 carriers. These findings warrant further investigation aimed at providing personalized cancer risks for male carriers and informing clinical management.